Trust Signals
Evidence standard: All claims graded by evidence type. Speculative claims are labeled. No undisclosed affiliate relationships with peptide vendors.
Regulatory note: In March 2024 the FDA finalized a rule placing BPC-157 on the list of bulk drug substances that cannot be used in compounding under 503A and 503B frameworks. This affects legal availability in the United States. Confirm current status in your jurisdiction before purchasing or using this compound.
Key Takeaways
- A 5 mg vial reconstituted with 2 mL bacteriostatic water yields 2,500 mcg per mL; a 250 mcg dose is exactly 0.10 mL (10 units on a 100-unit syringe).
- No human pharmacokinetic trial has established the optimal BPC-157 dose; the 250 to 500 mcg range is extrapolated from rat studies, not proven in humans.
- Reconstituted BPC-157 solution should be refrigerated at 2 to 8 degrees Celsius and discarded after roughly 28 days because no peer-reviewed peptide-specific stability data exists beyond that window.
- The FDA placed BPC-157 on its prohibited compounding list in 2024, meaning legally compounded BPC-157 is no longer available in the United States under current rules.
- The single most common injection error is drawing the wrong volume due to misreading insulin syringe units versus mL; confirm concentration before every draw.
Direct Answer: How Do You Take a BPC-157 Shot?
Knowing how to take a BPC-157 shot means reconstituting the lyophilized powder with bacteriostatic water, calculating the draw volume from your concentration, and injecting subcutaneously with a 29 to 31 gauge insulin syringe into the abdomen or near the injury site. Most research-derived protocols use 250 to 500 mcg once or twice daily, though no human dose-finding trial exists to confirm this range.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- Evidence Ledger: What Do We Actually Know?
- How Do You Reconstitute BPC-157 Powder?
- How Much BPC-157 Is in One Shot?
- How and Where Do You Inject BPC-157?
- What Most Protocol Pages Get Wrong
- How Long Does Reconstituted BPC-157 Last and Why?
- BPC-157 vs. Alternatives: Honest Comparison
- Label and COA Literacy: How to Judge Your Product
- What Are the Real Risks?
- FAQ
- Sources
Evidence Ledger: What Do We Actually Know?
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| BPC-157 accelerates tendon and ligament healing | Rat in vivo models (multiple, e.g., Brcic et al., Gjurasin et al.) | Positive vs. vehicle control in animals | Low (no human RCT) |
| BPC-157 promotes gut mucosal healing | Rat gastric ulcer and IBD models; some cell-line data | Positive in animal models | Low (no human RCT) |
| Subcutaneous injection is an effective delivery route | Animal PK inference; standard practice in rat studies | Effective in animals | Low (no human PK data) |
| 250 to 500 mcg is the appropriate human dose | Allometric scaling from rat studies (~10 mcg/kg) | Extrapolated only | Very Low |
| BPC-157 upregulates VEGF and affects nitric oxide pathways | Cell and animal mechanistic studies | Consistent directional finding | Moderate (mechanism); Low (clinical relevance) |
| Oral BPC-157 has gut effects | Rat models at higher doses | Positive in animals | Very Low (human bioavailability unknown) |
| BPC-157 is safe in humans at these doses | No published phase I human safety trial identified | Unknown | Very Low |
How Do You Reconstitute BPC-157 Powder?
BPC-157 is sold as a lyophilized (freeze-dried) powder, typically in 5 mg vials. Reconstitution requires bacteriostatic water (sterile water containing 0.9% benzyl alcohol as a preservative). Do not use plain sterile water for multi-draw vials because it contains no antimicrobial preservative.
Step-by-step:
- Wipe the vial stopper with a 70% isopropyl alcohol swab. Let it dry for 30 seconds.
- Draw the desired volume of bacteriostatic water into a syringe.
- Insert the needle at an angle and release the water slowly down the inner wall of the vial, not directly onto the powder cake. Forceful direct injection fragments the peptide aggregate and is thought to cause mechanical degradation, though peptide-specific kinetic data for this mechanism is not published.
- Do not shake. Swirl gently until the powder dissolves completely. The solution should be clear and colorless.
- Label the vial with the date of reconstitution and the resulting concentration.
Common reconstitution volumes and resulting concentrations for a 5 mg (5,000 mcg) vial:
| Bacteriostatic Water Added | Concentration (mcg/mL) | Volume for 250 mcg dose | Volume for 500 mcg dose |
|---|---|---|---|
| 1 mL | 5,000 mcg/mL | 0.05 mL (5 units) | 0.10 mL (10 units) |
| 2 mL | 2,500 mcg/mL | 0.10 mL (10 units) | 0.20 mL (20 units) |
| 5 mL | 1,000 mcg/mL | 0.25 mL (25 units) | 0.50 mL (50 units) |
Units refer to markings on a 100-unit (1 mL) insulin syringe. Confirm your syringe is 100-unit before reading the scale.
How Much BPC-157 Is in One Shot?
The honest answer is that no human dose-finding trial has been published. The most-cited animal studies (including work from Sikiric's group in Zagreb) used intraperitoneal or subcutaneous doses of roughly 10 mcg per kg in rats. Allometric scaling to a 75 kg human yields approximately 750 mcg, but allometric scaling of peptides is imprecise and does not account for human GI degradation, distribution differences, or receptor density variation.
Practitioner-reported protocols cluster around 250 to 500 mcg once or twice daily, which is a more conservative extrapolation. This range is not derived from a human phase I trial. It is a convention, not a proven optimum. State this clearly to anyone you advise.
How and Where Do You Inject BPC-157?
Needle recommendation: 29 to 31 gauge, 0.5-inch (12.7 mm) needle. This is the standard insulin syringe format and is appropriate for subcutaneous delivery in most abdominal sites. Longer needles risk inadvertent intramuscular injection in lean individuals.
Injection technique:
- Choose the site: abdomen (2 inches away from the navel), outer thigh, or an area near the affected tissue.
- Wipe the skin with an alcohol swab and let it dry completely. Injecting through wet alcohol stings and introduces alcohol into the tissue.
- Pinch the skin lightly to tent subcutaneous fat.
- Insert at a 45 to 90 degree angle depending on tissue depth.
- Draw back the plunger briefly to check for blood return. Blood in the syringe means you have entered a vessel; withdraw and choose a new site.
- Inject slowly, withdraw, and apply gentle pressure with a clean swab.
- Rotate sites to avoid lipohypertrophy, which is a real risk with repeated subcutaneous injections at any site.
Proximity-to-injury rationale: Some animal studies injected near the site of induced injury, and this is often repeated as a rule in forum protocols. There is no controlled human comparison of site-proximal versus remote subcutaneous injection. The rationale (higher local drug concentration near the lesion) is plausible but unproven in humans.
What Most Protocol Pages Get Wrong
This is the section commodity pages skip. Four specific errors appear repeatedly across medspa blogs and forum guides.
1. Confusing syringe units with mL without checking the syringe type. A 50-unit (0.5 mL) insulin syringe and a 100-unit (1 mL) insulin syringe both have markings that look similar. If you prepare a 2,500 mcg/mL solution and draw to "10" on a 50-unit syringe, you draw 0.20 mL (500 mcg), not 0.10 mL (250 mcg). Always verify total syringe capacity.
2. Treating allometric dose extrapolations as confirmed human doses. The 250 to 500 mcg range is an educated estimate, not a clinically validated dose. Presenting it as established is misleading and prevents users from making genuinely informed decisions.
3. Overlooking regulatory status. Most pages were written before the 2024 FDA rule change. BPC-157 is now on the FDA's list of substances that cannot be used in compounding under 503A and 503B. This is a material legal fact, not a technicality.
4. Not discussing purity and sourcing realistically. Research-grade peptides sold online have no mandatory third-party HPLC purity certification, no sterility testing requirement, and no FDA oversight. A product labeled 5 mg may contain significantly less active peptide, bacterial endotoxins, or related impurities. Unless a vendor provides a certificate of analysis (COA) from an independent, named laboratory with HPLC purity above 98% and endotoxin levels below 1 EU/mg, you cannot confirm what you are injecting.
How Long Does Reconstituted BPC-157 Last and Why?
Lyophilized BPC-157 is relatively stable because removing water slows hydrolysis and oxidation, the two primary degradation pathways for peptides.
Why bacteriostatic water extends vial life: The 0.9% benzyl alcohol in bacteriostatic water is a bacteriostatic (not sterilizing) agent. It inhibits microbial growth that would otherwise occur in a multi-draw vial opened repeatedly. Without it, bacterial contamination could occur within days at refrigerator temperatures.
Why cold storage matters: Peptide hydrolysis follows Arrhenius kinetics: reaction rate roughly doubles for every 10 degrees Celsius increase in temperature. Storing at 4 degrees Celsius versus 25 degrees Celsius substantially slows the backbone hydrolysis that breaks the peptide into inactive fragments. No published peptide-specific half-life data for BPC-157 in solution at 4 degrees Celsius has been identified in peer-reviewed literature. The 28-day guideline used by compounding pharmacies is a general peptide-in-solution convention, not a BPC-157-specific published stability study.
Signs of degradation to look for:
- Cloudiness or particulates in the reconstituted solution (clear is expected)
- Color change from clear to yellow or brown
- Lyophilized powder that appears yellow or clumped irregularly before reconstitution
- Loss of powder structure (no longer a cake; powder has collapsed or darkened)
HPLC testing is the only reliable method to confirm potency. Visual inspection only catches gross degradation.
BPC-157 vs. Alternatives: Honest Comparison
| Intervention | Evidence Tier (Healing) | Human Safety Data | Regulatory Status (US) | Where It Loses to BPC-157 | Where BPC-157 Loses |
|---|---|---|---|---|---|
| BPC-157 (injectable) | Animal only | None published | Not approved; banned from compounding 2024 | Not applicable (comparator) | No human RCT; legally restricted |
| Platelet-Rich Plasma (PRP) | Multiple RCTs (mixed results) | Good (autologous) | FDA-cleared device procedure | Some RCTs show no benefit vs. saline for tendinopathy | PRP has more human evidence; autologous means no contamination risk |
| Corticosteroid injection | Strong short-term RCT evidence | Well characterized | FDA approved | Long-term outcomes may be worse than placebo (Coombes et al., Lancet 2010) | Proven short-term pain relief; widely available |
| Physical therapy (tendon) | RCTs; first-line evidence | Excellent | Standard of care | Slower symptom relief than injections | PT has actual RCT evidence and no injection risk |
| TB-500 (Thymosin Beta-4) | Animal and some equine data | Very limited human data | Not approved | TB-500 has equine veterinary use history | Similar lack of human RCT data; similar regulatory risk |
Label and COA Literacy: How to Judge Your Product
When evaluating a BPC-157 product, request and read the COA from the vendor. A credible COA should contain all of the following:
- HPLC purity: Should state percentage purity with a chromatogram or method reference. Anything below 98% purity is substandard for a research-grade injectable peptide.
- Molecular weight confirmation: BPC-157 (sequence: GEPPPGKPADDAGLV) has a molecular weight of approximately 1,419 Da. Mass spectrometry confirmation on the COA confirms identity.
- Endotoxin (LAL) testing: A COA from a reputable lab will include limulus amebocyte lysate (LAL) testing. Endotoxin contamination from bacterial cell wall fragments causes fever and inflammatory responses even in sterile-appearing solutions. The USP limit for injectable peptides is generally below 5 EU/kg body weight per dose as a reference benchmark.
- Sterility testing: Confirms no viable microorganisms. This is distinct from endotoxin testing; a product can be sterile but still contain heat-stable endotoxins.
- Issuing laboratory: The COA should name a real, identifiable third-party analytical laboratory, not the vendor itself. A vendor-generated COA has no independent value.
What Are the Real Risks?
Known injection-site risks: Infection, pain, bruising, hematoma. These are risks of any subcutaneous injection and scale with technique quality and sterility.
Systemic risks (theoretical, not confirmed in humans): BPC-157 consistently upregulates VEGF (vascular endothelial growth factor) in animal studies. VEGF promotes angiogenesis, which is beneficial for wound healing but is also a pathway exploited by tumors. No human trial has studied BPC-157 in cancer patients or cancer survivors, and no causal human data exists linking BPC-157 to tumor promotion. However, the mechanistic signal is present and the absence of evidence is not evidence of absence given the lack of long-term human data.
The honest summary: We do not know the human safety profile of BPC-157 at injectable doses because no published human phase I safety trial exists. Users are accepting unknown risk, not low risk.
FAQ
How do you take a BPC-157 shot?
Reconstitute lyophilized BPC-157 with bacteriostatic water, draw the calculated volume into a 29 to 31 gauge insulin syringe, and inject subcutaneously near the site of injury or into the abdomen. Most research protocols use 250 to 500 mcg per injection once or twice daily.
What needle size is best for a BPC-157 injection?
A 29 to 31 gauge, 0.5-inch insulin syringe is standard for subcutaneous BPC-157 injections. The short needle reaches subcutaneous fat without risk of intramuscular delivery in most body sites.
How do you reconstitute BPC-157 powder?
Add bacteriostatic water slowly down the side of the vial, not directly onto the powder. A common ratio is 2 mL bacteriostatic water per 5 mg vial, yielding 2,500 mcg per mL. Do not shake; swirl gently until clear.
How much BPC-157 is in one shot?
Animal studies used roughly 10 mcg per kg of body weight. Extrapolated to a 75 kg adult that is approximately 750 mcg, but most practitioner protocols use 250 to 500 mcg per injection to stay conservative given the absence of human dose-finding trials.
Where do you inject BPC-157?
Most users inject subcutaneously in the abdomen or near the injury site. Proximity-to-injury dosing is a common rationale in animal research, but no controlled human trial has confirmed it produces better outcomes than a remote subcutaneous site.
How long does a reconstituted BPC-157 vial last?
Stored at 2 to 8 degrees Celsius and away from light, a reconstituted vial is generally considered stable for up to 28 days by peptide compounding pharmacies, though no published peer-reviewed stability kinetics exist for BPC-157 specifically.
Can you take BPC-157 orally instead of injecting?
Oral BPC-157 has shown effects in rat gut-injury models at higher doses, but peptides are subject to proteolytic degradation in the GI tract. Bioavailability data in humans does not exist. The injectable route is the one used in the majority of animal efficacy studies.
Is BPC-157 FDA approved?
No. BPC-157 has no FDA-approved indication. It is an unapproved research compound. In 2024 the FDA placed BPC-157 on its list of bulk drug substances that may not be used in compounding, which affects its legal availability in the United States.
What are the risks of injecting BPC-157?
Known injection risks include infection at the injection site, pain, bruising, and hematoma. Systemic risks are incompletely characterized because no phase II or III human safety trials exist. Theoretical concerns include effects on tumor angiogenesis given VEGF upregulation in animal models.
How do you calculate the draw volume for a BPC-157 injection?
Divide the desired dose in mcg by the concentration in mcg per mL. Example: 250 mcg dose divided by 2,500 mcg per mL equals 0.10 mL, which is 10 units on a 100-unit insulin syringe.
Does BPC-157 need to be refrigerated?
Lyophilized powder is relatively stable at room temperature for short periods but should be refrigerated for longer storage. Reconstituted solution must be refrigerated at 2 to 8 degrees Celsius and used within approximately 28 days.
How do you know if your BPC-157 has degraded?
Visual signs of degradation in the reconstituted solution include cloudiness, particulates, or a color change from clear to yellow or brown. Lyophilized powder that has turned yellow or clumped unevenly may also indicate degradation, though HPLC testing is the only reliable method.
Sources
- Sikiric P, Seiwerth S, Rucman R, et al. "Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157." Current Medicinal Chemistry, 2012. [Animal and mechanistic data series from Sikiric's Zagreb group.]
- Brcic L, Brcic I, Staresinic M, et al. "Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing." Journal of Physiology and Pharmacology, 2009. [Rat tendon model; VEGF upregulation finding.]
- Gjurasin M, Miklic P, Zupancic B, et al. "Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury." Regulatory Peptides, 2010. [Rat peripheral nerve model.]
- Coombes BK, Bisset L, Brooks P, Khan A, Vicenzino B. "Effect of corticosteroid injection, physiotherapy, or both on clinical outcomes in patients with unilateral lateral epicondylalgia." JAMA, 2013. [Context for corticosteroid comparison.]
- US FDA. "List of Bulk Drug Substances That May Not Be Used in Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act." Federal Register final rule, 2024. [Regulatory status of BPC-157.]
- United States Pharmacopeia (USP). General Chapter 1 (Injections and Implanted Drug Products): endotoxin limits and sterility guidance. [Endotoxin reference standard.]
- Uhlig C, Krause H, Koch R, et al. "Allometric scaling in pharmacology: general considerations." European Journal of Drug Metabolism and Pharmacokinetics, 2016. [Context for dose extrapolation limitations.]
Footer Disclaimers
Platform: FormBlends is an information and education platform. Nothing on this page constitutes medical advice, diagnosis, or a treatment recommendation. Consult a licensed healthcare provider before using any investigational compound.
Research Compound: BPC-157 is an unapproved research compound with no FDA-approved indication. As of 2024, it cannot be legally compounded in the United States under 503A or 503B pharmacy frameworks. Regulations vary by country.
Results: No results are guaranteed or implied. The evidence base for BPC-157 in humans is absent for efficacy and safety. Individual outcomes are unknown.
Trademark: All product names, peptide designations, and trademarks referenced are the property of their respective holders. FormBlends has no affiliation with any peptide vendor mentioned or implied.